Boston Financial Mangement LLC Sells 2,234 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Boston Financial Mangement LLC decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.8% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 44,421 shares of the biopharmaceutical company’s stock after selling 2,234 shares during the period. Boston Financial Mangement LLC’s holdings in Gilead Sciences were worth $3,724,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Manning & Napier Advisors LLC bought a new position in Gilead Sciences in the 2nd quarter valued at about $25,328,000. Legal & General Group Plc lifted its stake in Gilead Sciences by 0.8% during the 2nd quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company’s stock valued at $851,743,000 after acquiring an additional 93,068 shares in the last quarter. GSA Capital Partners LLP bought a new stake in shares of Gilead Sciences in the 1st quarter worth $462,000. Wealth Enhancement Advisory Services LLC grew its stake in shares of Gilead Sciences by 13.1% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 286,116 shares of the biopharmaceutical company’s stock worth $19,630,000 after acquiring an additional 33,162 shares in the last quarter. Finally, Cetera Investment Advisers raised its holdings in shares of Gilead Sciences by 127.6% in the first quarter. Cetera Investment Advisers now owns 213,901 shares of the biopharmaceutical company’s stock valued at $15,668,000 after purchasing an additional 119,909 shares during the last quarter. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Stock Down 0.3 %

Shares of NASDAQ:GILD opened at $88.76 on Tuesday. The company has a market cap of $110.58 billion, a price-to-earnings ratio of 246.56, a PEG ratio of 3.07 and a beta of 0.18. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $89.74. The firm has a fifty day moving average price of $82.75 and a two-hundred day moving average price of $73.62. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.14 and a quick ratio of 0.95.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.61 by $0.40. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. The business had revenue of $6.95 billion during the quarter, compared to analyst estimates of $6.64 billion. Analysts anticipate that Gilead Sciences, Inc. will post 3.76 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research note on Thursday, August 15th. Wells Fargo & Company upgraded Gilead Sciences from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $78.00 to $100.00 in a research note on Monday, October 7th. Raymond James upgraded Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 target price on the stock in a research note on Monday, July 8th. Truist Financial raised their price objective on shares of Gilead Sciences from $82.00 to $83.00 and gave the stock a “hold” rating in a report on Thursday, August 15th. Finally, Royal Bank of Canada boosted their target price on shares of Gilead Sciences from $74.00 to $75.00 and gave the company a “sector perform” rating in a research note on Friday, October 4th. Ten analysts have rated the stock with a hold rating, eleven have given a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $86.85.

Insider Activity

In other news, insider Johanna Mercier sold 29,357 shares of the company’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the sale, the insider now owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, insider Johanna Mercier sold 29,357 shares of the stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the sale, the insider now directly owns 78,127 shares in the company, valued at $6,545,480.06. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total transaction of $167,660.00. Following the completion of the transaction, the insider now directly owns 100,189 shares in the company, valued at approximately $8,398,843.87. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 36,847 shares of company stock worth $3,033,340. 0.16% of the stock is currently owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.